Pharmaceutical companies are becoming more organised in their approach and the Index leaders are increasingly coming to view access as a strategic issue. Access to medicine has landed in more boardrooms.

› Go to Key Findings

The industry is doing more to improve access to medicine than it was doing in 2010. Seventeen out of the 20 companies saw their scores increase and more companies have joined the ranks of the leaders.

› Go to Key Findings

Few companies report having robust measures to ensure clinical trials conducted by contractors are safe and ethical, with the majority providing no evidence of exerting real influence over the way their contractors conduct trials.

› Go to Key Findings

More companies are developing more products, and some now devote 20% of their pipeline to developing new products and adapting existing ones to address the needs of the poor.

› Go to Key Findings

More companies are using tiered pricing schemes, and applying them to a broader range of products and in more countries, but it is unclear whether the price reductions are enough to meaningfully increase affordability.

› Go to Key Findings

GlaxoSmithKline remains top of the league table, but its lead is shrinking, with two newcomers, Johnson & Johnson and Sanofi, moving into the top three closely behind and more companies joining the ranks of the leaders. The industry as a whole is gradually progressing.

› Go to Key Findings

Home

Methodology Highlights

Methodology Report

Index Ranking 2012

Latest News

2014 Access to Medicine Index – to be published November 17

15 October 2014 |

"We have the clearest ever picture of how the pharmaceutical industry is performing, and a deeper understanding of what it takes to be a leader,” Wim Leereveld, Index CEO and Founder.

› Read more

Investor meetings – 2014 Index in London, Paris, Basel

15 October 2014 |

Following its launch, the 2014 Access to Medicine Index will be presented to investors and other stakeholders at a series of meetings in Europe and the US. The meetings will provide an opportunity for selected investors, pharmaceutical analy

› Read more

Deutsche Bank draws on Access to Medicine Index for pharma analysis

23 September 2014 |

Titled “Tropical diseases; social responsibility, neglected market”, the new Deutsche Bank Markets Research report draws significantly on the 2012 Access to Medicine Index.

› Read more

Wim Leereveld to address WHO, WIPO, WTO symposium

1 September 2014 |

The symposium will take place on 5 November 2014 in Geneva, and will be opened by the Directors-General of the WHO, WIPO and WTO. Index Founder Wim Leereveld will address the changing role of pharmaceutical companies.

› Read more

Joep Lange will be greatly missed

18 July 2014 |

We were deeply saddened to learn that HIV pioneer Joep Lange died in the aircrash above Ukraine on 17 July. Joep Lange was a member of the Foundation’s Advisory Committee.

› Read more

How we Measure

What Leaders Say

Dr. Margaret Chan
Director-General, World Health Organization
"The Access to Medicine Index is a very important project. What gets measured, gets done."
Bill Gates
Chairman of Microsoft Corporation, Co-Chair and Trustee of the Bill & Melinda Gates Foundation
"When I talk to executives from pharmaceutical companies they tell me that they want to do more for neglected diseases, but they at least need to get credit for it. The Access to Medicine Index does exactly that."
Lilianne Ploumen
Minister for Foreign Trade and Development Cooperation, the Netherlands
“The Access to Medicine Index mobilizes the strength of the private sector, impacting the lives of millions of the most vulnerable people on earth. It showcases the synergy of aid, trade and investment.”
Knut Kjaer
Former CEO of RiskMetrics Group, Former CEO of Norges Bank Investment Management (NBIM) (1997-2007)
"Companies are beginning to understand that the value of corporate social responsibility programmes is not only the opportunity to do the right thing but that it's good for business as well. The Access to Medicine Index provides companies with a chance to improve performance and explore new business models while helping societies in need."

In the Media

Wim Leereveld talks to the Medicine Maker

29 September 2014 |

In the launch issue of The Medicine Maker, Index CEO and Founder Wim Leereveld tells the story of how the Index came into being, and gives his view on how the industry is progressing.

› Read more

Dr. Paul Newton refers to Access to Medicine Index in Lancet Global Health

22 September 2014 |

Writing in the September 2014 issue of The Lancet Global Health, Dr. Paul Newton et al discuss possible actions for addressing the dangers posed by falsified medicines.

› Read more

IP Watch talks to Hans Hogerzeil about how the Index works

20 March 2014 |

IP Watch interviews Hans Hogerzeil about how the Access to Medicine Index recognises good pharma practice, and about the importance of measuring companies' efforts to increase access to medicine.

› Read more

The Lancet Global Health publishes Index’s first longitudinal analysis

31 January 2014 |

Writing in The Lancet Global Health, Professor Hans Hogerzeil and members of the Index Research Team set out the findings of the first longitudinal analysis based on the Access to Medicine Index – you can read the report in full

› Read more

The Economist references the Access to Medicine Index

14 November 2013 |
The Economist profiles the Global Health Innovative Technology Fund (GHIT), a Japanese research partnership focused on developing treatments for malaria, tuberculosis and Chagas disease.
› Read more